Your browser doesn't support javascript.
loading
Integrative analysis of the plasma proteome and polygenic risk of cardiometabolic diseases.
Ritchie, Scott C; Lambert, Samuel A; Arnold, Matthew; Teo, Shu Mei; Lim, Sol; Scepanovic, Petar; Marten, Jonathan; Zahid, Sohail; Chaffin, Mark; Liu, Yingying; Abraham, Gad; Ouwehand, Willem H; Roberts, David J; Watkins, Nicholas A; Drew, Brian G; Calkin, Anna C; Di Angelantonio, Emanuele; Soranzo, Nicole; Burgess, Stephen; Chapman, Michael; Kathiresan, Sekar; Khera, Amit V; Danesh, John; Butterworth, Adam S; Inouye, Michael.
Afiliação
  • Ritchie SC; Cambridge Baker Systems Genomics Initiative, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. sr827@medschl.cam.ac.uk.
  • Lambert SA; Cambridge Baker Systems Genomics Initiative, Baker Heart & Diabetes Institute, Melbourne, Victoria, Australia. sr827@medschl.cam.ac.uk.
  • Arnold M; British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. sr827@medschl.cam.ac.uk.
  • Teo SM; British Heart Foundation Centre of Research Excellence, University of Cambridge, Cambridge, UK. sr827@medschl.cam.ac.uk.
  • Lim S; Cambridge Baker Systems Genomics Initiative, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Scepanovic P; Cambridge Baker Systems Genomics Initiative, Baker Heart & Diabetes Institute, Melbourne, Victoria, Australia.
  • Marten J; British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Zahid S; Health Data Research UK Cambridge, Wellcome Genome Campus and University of Cambridge, Cambridge, UK.
  • Chaffin M; British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Liu Y; Cambridge Baker Systems Genomics Initiative, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Abraham G; Cambridge Baker Systems Genomics Initiative, Baker Heart & Diabetes Institute, Melbourne, Victoria, Australia.
  • Ouwehand WH; Cambridge Baker Systems Genomics Initiative, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Roberts DJ; Cambridge Baker Systems Genomics Initiative, Baker Heart & Diabetes Institute, Melbourne, Victoria, Australia.
  • Watkins NA; British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Drew BG; Cambridge Baker Systems Genomics Initiative, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Calkin AC; Cambridge Baker Systems Genomics Initiative, Baker Heart & Diabetes Institute, Melbourne, Victoria, Australia.
  • Di Angelantonio E; British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Soranzo N; Cambridge Baker Systems Genomics Initiative, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Burgess S; British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Chapman M; Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Kathiresan S; Department of Medicine, Harvard Medical School, Boston, MA, USA.
  • Khera AV; Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Danesh J; Lipid Metabolism & Cardiometabolic Disease Laboratory, Baker Heart & Diabetes Institute, Melbourne, Victoria, Australia.
  • Butterworth AS; Molecular Metabolism & Ageing Laboratory, Baker Heart & Diabetes Institute, Melbourne, Victoria, Australia.
  • Inouye M; Cambridge Baker Systems Genomics Initiative, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Nat Metab ; 3(11): 1476-1483, 2021 11.
Article em En | MEDLINE | ID: mdl-34750571
ABSTRACT
Cardiometabolic diseases are frequently polygenic in architecture, comprising a large number of risk alleles with small effects spread across the genome1-3. Polygenic scores (PGS) aggregate these into a metric representing an individual's genetic predisposition to disease. PGS have shown promise for early risk prediction4-7 and there is an open question as to whether PGS can also be used to understand disease biology8. Here, we demonstrate that cardiometabolic disease PGS can be used to elucidate the proteins underlying disease pathogenesis. In 3,087 healthy individuals, we found that PGS for coronary artery disease, type 2 diabetes, chronic kidney disease and ischaemic stroke are associated with the levels of 49 plasma proteins. Associations were polygenic in architecture, largely independent of cis and trans protein quantitative trait loci and present for proteins without quantitative trait loci. Over a follow-up of 7.7 years, 28 of these proteins associated with future myocardial infarction or type 2 diabetes events, 16 of which were mediators between polygenic risk and incident disease. Twelve of these were druggable targets with therapeutic potential. Our results demonstrate the potential for PGS to uncover causal disease biology and targets with therapeutic potential, including those that may be missed by approaches utilizing information at a single locus.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Sanguíneas / Herança Multifatorial / Proteoma / Cardiopatias / Doenças Metabólicas Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Nat Metab Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Sanguíneas / Herança Multifatorial / Proteoma / Cardiopatias / Doenças Metabólicas Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Nat Metab Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido